Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 2
2012 3
2013 2
2015 2
2016 1
2018 2
2019 5
2020 2
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T, Takagi M, Sato-Otsubo A, Nishimura A, Nagae G, Yamagishi C, Tamura M, Tanaka Y, Asada S, Takeda R, Tsuchiya A, Wang X, Yoshida K, Nannya Y, Ueno H, Akazawa R, Kato I, Mikami T, Watanabe K, Sekiguchi M, Seki M, Kimura S, Hiwatari M, Kato M, Fukuda S, Tatsuno K, Tsutsumi S, Kanai A, Inaba T, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Kotecha RS, Cruickshank MN, Ishikawa F, Morio T, Eguchi M, Deguchi T, Kiyokawa N, Arakawa Y, Koh K, Aoki Y, Ishihara T, Tomizawa D, Miyamura T, Ishii E, Mizutani S, Wilson NK, Göttgens B, Miyano S, Kitamura T, Goyama S, Yokoyama A, Aburatani H, Ogawa S, Takita J. Isobe T, et al. Among authors: cruickshank mn. Nat Commun. 2022 Aug 30;13(1):4501. doi: 10.1038/s41467-022-32266-4. Nat Commun. 2022. PMID: 36042201 Free PMC article.
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Cheung LC, et al. Among authors: cruickshank mn. Leukemia. 2023 Jan;37(1):61-71. doi: 10.1038/s41375-022-01746-3. Epub 2022 Nov 15. Leukemia. 2023. PMID: 36380143 Free PMC article.
Single cell transcriptomics reveals cell type specific features of developmentally regulated responses to lipopolysaccharide between birth and 5 years.
Read JF, Serralha M, Armitage JD, Iqbal MM, Cruickshank MN, Saxena A, Strickland DH, Waithman J, Holt PG, Bosco A. Read JF, et al. Among authors: cruickshank mn. Front Immunol. 2023 Oct 17;14:1275937. doi: 10.3389/fimmu.2023.1275937. eCollection 2023. Front Immunol. 2023. PMID: 37920467 Free PMC article.
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
Wang E, Sorolla A, Cunningham PT, Bogdawa HM, Beck S, Golden E, Dewhurst RE, Florez L, Cruickshank MN, Hoffmann K, Hopkins RM, Kim J, Woo AJ, Watt PM, Blancafort P. Wang E, et al. Among authors: cruickshank mn. Oncogene. 2019 Jan;38(1):140-150. doi: 10.1038/s41388-018-0421-y. Epub 2018 Aug 3. Oncogene. 2019. PMID: 30076412 Free PMC article.
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.
Cheung LC, Cruickshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS. Cheung LC, et al. Among authors: cruickshank mn. Haematologica. 2019 Jul;104(7):e300-e303. doi: 10.3324/haematol.2018.192906. Epub 2019 Jan 24. Haematologica. 2019. PMID: 30679330 Free PMC article. No abstract available.
21 results